ARID1A and hepatocellular carcinoma: Therefore, to prove that inhibition of TEAD1 is specifically synthetic lethal to ARID1A loss-of-function, we employed two HCC-derived cell lines carrying a wild-type ARID1A–Huh-7 and HLE, and modulated ARID1A and TEAD1 expression using siRNAs (Supplementary Fig. 4a, b).